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Abstract: Fibromyalgia is a complex chronic condition characterized by pain, physical fatigue,
sleep disorder and cognitive impairment. Evidence-based guidelines recommend antidepressants
as treatments of fibromyalgia where tricyclics are often considered to have the greatest efficacy,
with amitriptyline often being a first-line treatment. Amitriptyline evokes a preferential reduction
in pain and fatigue of fibromyalgia, and in the Fibromyalgia Impact Questionnaire (FIQ) score,
which is a quality of life assessment. The multimodal profile of the mechanisms of action
of amitriptyline include monoamine reuptake inhibition, receptor modulation and ion channel
modulation. Several of the actions of amitriptyline on multiple nociceptive and sensory processes at
central and peripheral locations have the potential to act cumulatively to suppress the characteristic
symptoms of fibromyalgia. Greater understanding of the role of these mechanisms of action of
amitriptyline could provide further clues to the pathophysiology of fibromyalgia and to a preferable
pharmacological profile for future drug development.
Keywords: fibromyalgia; amitriptyline; monoamine transporters; pain; fatigue; Fibromyalgia
Impact Questionnaire
1. Introduction
Fibromyalgia is a complex chronic condition characterized by widespread pain, physical fatigue,
non-restorative sleep and cognitive impairment [1,2]. A high incidence of co-morbidities, such
as depression, irritable bowel syndrome, headache and temporomandibular joint dysfunction,
with variable intensity are reported [1,2]. The worldwide prevalence of fibromyalgia, based on
application of the American College of Rheumatology (ACR) 1990 criteria, has been reported to range
from 0.4% to 8% of the population, with the condition being more common in females [3]. Fibromyalgia
is therefore a major social and financial burden for patients and healthcare systems warranting effective
and safe treatment options. Amplified responses of the central nervous system (CNS) to peripheral
sensory input leading to enhanced neuronal excitability and central sensitization have been reported to
be associated with hyperalgesia and allodynia, which are symptoms characteristic of fibromyalgia [1].
Thus, pharmacological treatments of fibromyalgia are usually focused on lowering pronociceptive
excitatory neurotransmission and/or increasing antinociceptive neurotransmission in the CNS [2].
The evidence-based guidelines of the European League Against Rheumatism (EULAR) and
the Association of Medical Scientific Societies in Germany (AWMF) recommend antidepressants,
such as amitriptyline, duloxetine and milnacipran, as pharmacological therapies for fibromyalgia [4–6].
Although antidepressants are commonly used in the treatment of chronic pain, the efficacy varies
depending on the type and mechanism of action of the drug and the specific condition being treated [7].
Antidepressants act on noradrenergic and serotonergic neurons, which are implicated in the mediation
of endogenous pain inhibitory mechanisms and associated with several aspects of the pathophysiology
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of fibromyalgia [1,8]. Descending serotonergic-noradrenergic and opioidergic efferent pathways,
which form the diffuse noxious inhibitory control (DNIC), are activated in healthy subjects by the
application of intense painful stimuli leading to downregulation of the pain signal. In patients with
fibromyalgia, the DNIC has been reported to be reduced or absent [9]. Consistent with decreased
endogenous serotonergic and noradrenergic activity and a reduced DNIC in patients with fibromyalgia
is an altered biochemistry of serotonin and noradrenaline. Lower levels of main metabolites of serotonin
and noradrenaline, 5-hydroxyindoleacetic acid (5-HIAA) and 3-methoxy-4-hydroxyphenethylene glycol
(MHPG) respectively, in cerebrospinal fluid and of L-tryptophan and serotonin in blood are observed in
patients with fibromyalgia compared to healthy controls [1,8].
This review will focus on the pharmacology of amitriptyline that could be responsible for the
benefits observed in the treatment of fibromyalgia.
2. Pharmacology of Antidepressants and Fibromyalgia
Serotonin reuptake transporters (SERT) and noradrenaline reuptake transporters (NET) are
the main targets of antidepressants, such as tricyclic antidepressants (TCAs, e.g., amitriptyline),
selective serotonin reuptake inhibitors (SSRIs, e.g., fluoxetine), serotonin and noradrenaline
reuptake inhibitors (SNRIs, e.g., duloxetine and milnacipran) and selective noradrenaline reuptake
inhibitors (NRIs, e.g., reboxetine). The affinities for monoamine reuptake transporters and
selected neurotransmitter receptors of antidepressant drugs tested as treatments of fibromyalgia are
summarized in Table 1 [10–21]. These antidepressants, through pharmacological actions onmonoamine
reuptake transporters, can facilitate the endogenous pain control system at neuroanatomical structures
such as the locus coeruleus nucleus, the dorsal and magnus nuclei in the raphe, and the dorsal
horn of the spinal cord [22]. A pathway from the midbrain periaqueductal gray (PAG) through
the ventromedial medulla (VMM) to the dorsal horn constitutes a putative endogenous nociceptive
modulatory system [23]. Evidence supports the PAG and VMM having multiple and coordinated
effector functions that are not limited to nociceptive modulation but may involve homeostatic
functions such as sleep-awake cycle, micturition and blood pressure [23]. A reciprocal feedback
exists between the raphe nuclei and the suprachiasmatic nuclei, contributing to circadian rhythms
and alteration of serotonin levels controlling sleep-awake states [24]. The locus coeruleus is a
principal area for the synthesis of noradrenaline in the brain which, in addition to involvement
in pain and stressor responses, mediates arousal of the sleep-awake cycle [25]. Consequently, many of
the sympathetic effects during stress are mediated by the locus coeruleus increasing noradrenaline
secretion and the raised noradrenaline levels alter, via a multimodal process, cognitive function
through the prefrontal cortex [25,26]. Thereby, modulation of serotonin and noradrenaline levels,
particularly within the descending processes, by the action of antidepressants on the monoamine
reuptake transporters, has the potential of changing, in addition to pain, many of the characteristic
symptoms of fibromyalgia. The involvement of serotonin and noradrenaline levels in the efficacy of
antidepressants in fibromyalgia identifies 5-hydroxytryptamine (5-HT) and adrenergic receptors
as playing a significant role in antinociceptive properties. Affinity for and/or efficacy at 5-HT
and adrenergic receptors exhibited by antidepressants could influence the pain reducing profile
but also result in unwanted effects [27,28]. Although action at muscarinic and histamine receptors
of antidepressants has been related to the adverse cardiotoxicity and gastrointestinal disturbance,
and sedative properties respectively, antinociceptive effects may also be achieved by actions at these
receptors [27,28]. The efficacy of antidepressant drugs tested as treatments of fibromyalgia on the
characteristic symptoms and quality of life assessments are summarized in Table 2 [29–70].
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Table 1. Summary of affinities of antidepressant drugs for monoamine reuptake transporters and neurotransmitter receptors. Data are presented as concentrations
(nM) representing binding to the protein (Ki value) or exhibiting 50% inhibition of the protein function (IC50); where multiple values are available, a range of the
published values is presented. For 5-hydroxytryptamine (5-HT) and histamine receptors, subtypes are indicated in parentheses after the data values. For receptor
subtypes not stated, IC50 value was >10,000 nM. NET is the noradrenaline reuptake transporter; SERT is the serotonin reuptake transporter; DAT is the dopamine
reuptake transporter. N/A = not available.
Drug
NET SERT DAT
Receptors
ReferencesAdrenergic Muscarinic Histamine 5-HT
Ki/IC50 nM Ki/IC50 nM Ki/IC50 nM IC50 nM IC50 nM IC50 nM IC50 nM
Amitriptyline 13.3–63 3.13–67 2580–7500 24–690 7.2–26 1.1(H1), 1000(H3), 33.6(H4) 450(1A), 40(1B), 4(2A), 40(2B), 6(2C), 89–103(6), 126–398(7) [10–12]
Citalopram 4870–>10,000 1.13–19.0 >10,000 560–1211 1430 180–286 617–6000(2) [10,13,14]
Cyclobenzaprine 126 251 7943 10–110 8–30 1–6 20(2A), 200(2B), 62(2C), 40(6), 69(7) [11]
Duloxetine 1.17–42 0.07–13 200–439 8300–8600 3000 2300 504(2A), 419(6) [10,15–19]
Fluoxetine 563–1021 1.0–10 4180 3000 870–2700 3250 200(2A), 5000(2B), 73(2C) [12,16,18,20]
Milnacipran 22–200 8.4–151 >100,000 >10,000 >10,000 >10,000 >10,000 [10,16,18,19]
Nortriptyline 1.49–8.3 16.5–317 1200–5000 55–2030 40–110 15.1(H1) 294(1A), 5(2A), 8.5(2C), 148(6) [10,12]
Paroxetine 100–156 0.34–2 963 2741 72–340 >10,000 9034(2C) [12,14,16,20]
Reboxetine 3–13.4 242–274 >10,000 >10000 6700 312 457(2C) [12,14,16]
Sertraline 715–925 0.9–2.8 315 188 427 6578 2298(2C) [18,20]
TD-9855 2–4 3–10 160–200 N/A N/A N/A N/A [21]
Trazodone >10,000 367 >7000 153–728 >10,000 220(H1), 3290(H2) 118(1A), 106(1D), 36(2A), 78(2B), 224(2C), 1780(7) [12]
Venlafaxine 538–2483 7.8–145 3070–7647 >10,000 >10,000 >10,000 2000(2), 2800(6) [10,13,16–19]
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Table 2. Efficacy of antidepressant drugs in the treatment of fibromyalgia. Data are presented based on the effects of antidepressant drugs on the Fibromyalgia Impact
Questionnaire (FIQ), Patient’s Global Impression Assessment and primary symptoms. Changes in score ratings are presented on a 0 to 10 scale, except FIQ (0–100),
Hamilton Rating Scale for Depression (HDRS), Hamilton Anxiety Rating Scale (HAM-A; 0–56), Beck Depression Inventory (BDI; 0–63), Beck Anxiety Inventory
(BAI; 0–63), and Montgomery–Åsberg Depression Rating Scale (MADRS; 0–60). The proportion (%) of patient population gaining significant benefit for a domain,
where available, is indicated by #. MOS = Sleep Scale from the Medical Outcomes Study; VLD = very low dose.
Drug Dose (mg/day) FIQ Patient’s Global Assessment
Symptoms References
Pain Fatigue Sleep Anxiety and Depression
Amitriptyline 10–100 −13 to −19 −0.5 to −3.8 87% # −0.4 to −5.3
−2.2 to 3.5
80−93% # −1.1 to −3.9 63−100%
# HDRS −9.9 to −10.4 BDI
−6.2 to −7.0 50% # [29–41]
Citalopram 20–40 52.9% # −1.2 −0.59 MADRS −4.0 [42]
Cyclobenzaprine
(TNX102SL) 10 VLD 1–4 −0.9 No effect Parameters improved 12.3−38.5% Improved 24.1% [43–47]
Duloxetine 30–120 −7.96 to −18.4 −2.79 to −3.43 −1.6 to −2.4 −0.33 to −3.8 −2.67 to −2.69 Caused insomnia BDI −3.32 to −5.47 HDRS
−2.04 to −7.8 [48–56]
Esreboxetine 4–10 −3.9 to −7.2 40−42.6% # −0.4 to −0.76 −0.59 to −0.64 Caused insomnia [57]
Fluoxetine 10–80 −10.9 to −11.5 −1.77 −2.3 to −2.4 −1.6 −0.86 No effect [32,58]
Milnacipran 30–200 −12.3 to −26 35−51% # −1.6 to −3.5 −4.3 to −7.3 No effect BDI −2.1 to −4.9 [59–63]
Paroxetine 12.5–62.5 −6.6 to −6.8 45−55% # −0.95 −4.6 to −4.9 BDI −4.6 to −5.8 [64,65]
Sertraline 50 83% # −4.2 MOS Score −15 [66]
TD-9855 20 −16.2 48% # −1.4 Caused insomnia [67]
Trazodone 50–300 −9.6 to −13.4 −0.52 to −1.41 −0.72 to −1.17 −4.2 to −5.0
HDRS −1.4 to −2.0
HAM-A −1.5 to −2.4 BDI
−5.5 to −8.9
[68]
Venlafaxine 75–300 −9.0 to −19.9 51% # −1.87 to −2.14 35% #
HDRS −3.6 to −4.65
HAM-A −7.14 to −13.5
BAI −8.5
BDI −7.9
[34,69]
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The optimum analgesic action of antidepressants in the treatment of fibromyalgia, as with other
chronic pain conditions, is usually achieved with a dose lower than that required to achieve mood
enhancement indicative of intrinsic analgesic efficacy [22]. Although the analgesic response is distinct
from the effects on mood as indicated by the variation in analgesic efficacy among the chemical classes,
many of the antidepressants over the dose range used in the treatment of fibromyalgia also reduce
anxiety and depression scores (Table 2). Antidepressants exhibit diverse pharmacological properties
with individual agents (within a class) exhibiting such effect to variable degrees, and this may account
for possible differing outcomes in the treatment of fibromyalgia.
3. Pharmacology of Amitriptyline and Fibromyalgia
Of the range of antidepressant classes (TCAs, SNRIs, SSRIs, NRIs), TCAs are often considered
to have the greatest analgesic efficacy, with amitriptyline (10–50 mg/day) being recommended
as a first-line treatment for fibromyalgia [4–6]. The use and acceptance of TCAs in patients with
fibromyalgia will be enhanced by the adverse effects often reported for this class of drugs occurring
less commonly and with less severity when used as analgesics than as antidepressants [22].
A preferential outcome in the reduction of pain and fatigue associated with fibromyalgia and
in the Fibromyalgia Impact Questionnaire (FIQ) score, which reflects a quality of life assessment,
was observed with amitriptyline (10–100 mg/day) compared to the majority of other antidepressants
(Figure 1; Table 2). The efficacy of amitriptyline relative to other classes of antidepressants (e.g., SNRIs,
SSRIs and NRIs) infers that modulation of monoamine reuptake mechanisms and additional
pharmacological properties are required to control the symptoms of fibromyalgia.
Although amitriptyline evokes a relatively balanced inhibition of serotonin and noradrenaline
reuptake, the main metabolite, nortriptyline, preferentially inhibits noradrenaline reuptake
(Table 1) [70]. Thus, in a clinical setting, the net outcome of amitriptyline treatment will place an
emphasis on inhibiting noradrenaline reuptake, which may be relevant to changes in the biology
of patients with fibromyalgia. For example, an increased release of substance P, a mediator of
C fibres which contributes to central sensitization, is expressed as hyperalgesia if noradrenergic
neuronal activity or the levels of noradrenaline decrease [71]. In patients with fibromyalgia, substance
P levels are raised in the cerebrospinal fluid which could induce pain through the activation of
neurokinin 1 receptors [8]. In addition to inhibiting presynaptic reuptake of noradrenaline and
serotonin, amitriptyline has affinity for α-adrenergic, histamine, muscarinic cholinergic, 5-HT,
N-methyl-D-aspartate (NMDA) and opioid receptors (Table 1) [12].
Although pain in patients with fibromyalgia is probably mediated by alternating activity levels in
the CNS, associated with hyperexcitability, peripheral nociceptive generators enhancing the symptoms
also play a role in the pathophysiology and need to be considered in the management of the
condition [1,2,8]. A peripheral analgesic effect of antidepressants has been proposed [72]. Inhibition of
the monoamine reuptake transporters, however, is unlikely to be the mechanism of action responsible
for the analgesic properties of amitriptyline, because noradrenaline and serotonin enhance nociceptive
transmission at a peripheral level. Thus, blockade of adrenoceptors and 5-HT receptors, and possibly
of histamine and muscarinic receptors, as observed with amitriptyline but not SNRIs and SSRIs,
is a more likely contributory analgesic mechanism of action at a peripheral level in patients with
fibromyalgia [22]. Peripheral adenosine A1 receptors have also been proposed to be involved in
systemically administered amitriptyline-induced antinociception [73]. Amitriptyline and other TCAs
inhibit the neuronal uptake of adenosine which would lead to enhanced stimulation of adenosine
receptors at both peripheral and CNS levels producing analgesia [28]. Interestingly, raised adenosine
levels associated with D-ribose treatment have been reported to reduce symptoms in patients with
fibromyalgia [74].
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Figure 1. Schematic of monoamine transporter selectivity and efficacy of antidepressant drugs to Figure 1. Schematic of monoamine transporter selectivity and efficacy of antidepressant drugs to
reduce pain (A), fatigue (B) and Fibromyalgia Impact Questionnaire (FIQ) score (C) in patients
with fibromyalgia. Selectivity ratios for the antidepressant drugs were determined from affinity and
inhibitory properties for noradrenaline reuptake transporter (NET) and serotonin reuptake transporter
(SERT) where NA indicates a selectivity for NET over SERT values and 5-HT indicates a selectivity
for SERT over NET (see Table 1). Pain measurement (A) is presented as change on a 0–10 scale visual
analogue scale (VAS); fatigue measurement (B) is presented as change on a 0–10 scale VAS; FIQ score
(C) is presented as a change on a 0–100 scale (see Table 2). TCAs are indicated in red, SNRIs in blue,
SSRIs in green and NRIs in purple.
Although amitriptyline has been demonstrated to bind to opioid receptors and NMDA
receptors, interaction with these receptors at therapeutic drug concentrations has been the subject of
debate [70]. Antidepressants binding to the NMDA receptor reduce glutamate-induced intracellular
calcium accumulations which would lead to suppression of cell excitation [75,76]. The neuronal
hyperexcitability that is observed in fibromyalgia, causing both spontaneous and stimulus-evoked
pain, may be a consequence of heightened sensitivity of the NMDA receptor-operated ion channels,
which could have an impact on the concentrations of amitriptyline evoking a therapeutic effect [77].
The opioidergic system also appears to be involved in the mechanism of action of certain
antidepressants that have antihyperalgesic action, such as TCAs, but not those with antinociceptive
effects (e.g., duloxetine), which is an analgesic profile that would be relevant to the symptoms
characteristic of fibromyalgia [78].
At therapeutic drug concentrations, amitriptyline also interacts with sodium, calcium and
potassium channels. TCAs block open and inactivated states of sodium channels by binding to
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the local anaesthetic receptor, a property that may contribute to the analgesic efficacy in patients with
fibromyalgia [79]. Although the action at potassium channels has been suggested to be involved in the
adverse effects of amitriptyline (e.g., cardiac events), the role of interaction with specific calcium and
potassium channel subtypes at therapeutic concentrations with the beneficial effects in humans needs
further investigation. Central antinociception induced by amitriptyline has been reported to involve
the opening of different subtypes of K+ channels (voltage-gated Kv1.1, KATP and Ca2+-gated) which
represent important intracellular effectors in the analgesic activity of TCAs [80]. Further, amitriptyline
has an affinity for the Kv7 family of potassium channels, which are the targets of potential treatments
of fibromyalgia [81,82].
Dopamine deficiency in the CNS has also been implicated in the pathophysiology of fibromyalgia,
with a decrease in dopamine concentration leading to central pain sensitization [83]. There may also
be a correlation between the decrease in dopamine levels and other symptoms of fibromyalgia such as
fatigue, sleep disturbances and depression. This has raised interest in direct or indirect dopaminergic
actions as a potential mechanism for the treatment of fibromyalgia. Although amitriptyline
has been suggested to exhibit limited effects on the dopaminergic system, the combination of
amitriptyline and fluoxetine as a treatment of fibromyalgia was suggested to offer a preferable
serotonin/noradrenaline/dopamine uptake inhibition than what was provided by the individual
drugs [32]. Sertraline and TD-9855 offer a reduction of the pain and fatigue levels, and they have
a FIQ score similar to amitriptyline (Figure 1); however, they are more potent inhibitors of the
dopamine reuptake transporter (Table 1). This additional property of sertraline and TD-9855 may
enhance the symptom-relieving effects obtained with serotonergic and noradrenergic mechanisms of
action. Bupropion has been reported to inhibit the dopamine reuptake transporters and NETs, but not
the neuronal reuptake of serotonin [84]. A case study in a patient with fibromyalgia reported that
bupropion improved pain scores and other fibromyalgia symptoms such as depression and cognitive
function, over a two-month period [85]. Sibutramine, a serotonin/noradrenaline/dopamine reuptake
inhibitor, has also been shown to reduce pain and fatigue, and increase overall functioning in patients
with fibromyalgia [86]. Involvement of the dopamine system in the actions of amitriptyline as a
treatment of fibromyalgia is worthy of further consideration.
A multimodal action of amitriptyline in fibromyalgia probably involves CNS and peripheral
targets with contributory actions on receptors and ion channels in addition to monoamine
reuptake inhibition.
4. Conclusions
Treatment of fibromyalgia remains a major unmet medical need and optimal translation of
current research to the clinic has been limited. Nociceptive signalling involves a range of receptors,
mediators, cells, and physiological and genetic changes supporting the need to target multiple events
to evoke effective control of the symptoms of diverse patients with fibromyalgia. Consequently,
drugs that act through diverse mechanisms and that are given as combination therapy are often
standard for the treatment of fibromyalgia [4–6,87]. Several of the actions of amitriptyline have the
potential to cumulatively interfere with, at least, the pain mechanism in fibromyalgia. Relative to other
antidepressants (SNRIs, SSRIs, NRIs), TCAs could be more effective as analgesics because of their
actions on multiple nociceptive and sensory targets at central and peripheral levels.
The heterogeneity of fibromyalgia has led to the proposal of the existence of subgroups of
patients [88]; however, analgesic drug development is based on the mean responses of groups of
patients with the same condition given the same drug and dose, with individual subjects or subgroups
of the patient population given little consideration [89]. With such a heterogeneous condition,
effectiveness is going to be dependent on multimodal pharmacology, as exhibited by amitriptyline.
Understandably, involvement of a diverse pharmacology has the potential of increasing the incidence
and profile of adverse effects which may lead many patients to discontinue use. Greater understanding
of the role of the mechanisms of action of amitriptyline in the management of the symptoms of
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fibromyalgia requires further investigation to provide clues about the pathophysiology of the condition
and to provide a preferable pharmacological profile for future drug development.
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